RxDoctor Payments Data

Jason Reinhart, DO

Neurology · Glendale, AZNPI 1629049978

Payments from drug & device makers

$16,987in general payments, 2019–2025

Across 1,171 payments — averaging $14.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • Teva Pharmaceuticals USA, Inc.$2K
  • UCB, Inc.$2K
  • AbbVie$1K
  • Lilly USA, LLC$931
  • EMD Serono, Inc.$839
  • plus $8K from 54 others

What the payments were for

  • Speaking & faculty fees$580%
  • Food & beverage$16,64198%
  • Education$2882%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis184$2,328
Teva Pharmaceuticals USA, Inc.133$1,668
UCB, Inc.115$1,570
AbbVie(2 entities)95$1,125
Lilly USA, LLC78$931
EMD Serono, Inc.51$839
Banner Life Sciences, LLC63$760
Biogen52$753
Sanofi30$530
Amgen(2 entities)31$501
Acadia Pharmaceuticals Inc29$499
Argenx US, Inc.30$442
Amneal Pharmaceuticals LLC23$354
SK Life Science, Inc.20$337
Supernus Pharmaceuticals, Inc.25$305
Abbott14$295
Pfizer21$283
Eisai Inc.15$277
AstraZeneca12$273
Genentech USA, Inc.15$234
Impel Pharmaceuticals Inc.10$182
Neurocrine Biosciences, Inc.9$178
Acorda Therapeutics, Inc10$174
Neurelis, Inc.7$134
Sunovion Pharmaceuticals Inc.11$128
Vertiflex, Inc.2$115
Avion Pharmaceuticals6$112
Bristol Myers Squibb5$100
TG Therapeutics, Inc.4$100
Sanofi-aventis U.S. LLC1$99
Cycle Pharmaceuticals Inc3$82
Avanir Pharmaceuticals, Inc.4$75
Scilex Pharmaceuticals Inc.4$73
Grifols USA, LLC3$73
Otsuka America Pharmaceutical, Inc.3$62
Upsher-smith Laboratories LLC3$57
Biohaven Pharmaceuticals, Inc.3$56
Kyowa Kirin, Inc.2$54
Tanabe Pharma America, Inc.3$53
Neuropace, Inc.3$52
C2n Diagnostics, LLC2$51
Sumitomo Pharma America, Inc.3$47
Corium, LLC3$47
Stryker1$45
Nevro Corp.2$42
Biohaven Pharmaceutical Holding Company Ltd.2$39
Aucta Pharmaceuticals, Inc.3$38
Mallinckrodt Enterprises LLC2$34
Almatica Pharma LLC2$34
Insightec,inc1$29
Medtronic1$28
Arbor Pharmaceuticals, Inc.2$27
Boston Scientific1$27
Vanda Pharmaceuticals Inc.1$25
Harmony Biosciences LLC1$21
Aprecia Pharmaceuticals, LLC1$21
Akcea Therapeutics, Inc.1$20
Shire North American Group Inc1$19
Cala Health, Inc.1$19
Mallinckrodt Hospital Products Inc.1$18

How this compares

$16,987 in reported general payments places this provider in the 65th percentile of 388 neurology providers in Arizona.

See all neurology providers in Arizona

Medicare billing

Part B allowed, 2024
$445,779
Medicare patients
1,001
Services billed
3,065

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab13$124,902
Emgality PenGalcanezumab-Gnlm37$38,363
Aimovig AutoinjectorErenumab-Aooe18$22,854
Nurtec OdtRimegepant Sulfate12$20,521
NeuproRotigotine13$16,722
QuliptaAtogepant15$15,965
Gabapentin471$13,433
Ajovy AutoinjectorFremanezumab-Vfrm12$12,467
Duloxetine Hcl186$6,644
Memantine Hcl131$6,060
Carbidopa-LevodopaCarbidopa/Levodopa138$4,728
Primidone111$3,919
Levetiracetam70$3,835
Lacosamide39$3,816
Donepezil Hcl273$3,412

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$283$20,52112 claims
UCB, Inc.Neupro$1,570$16,72213 claims
AbbVieQulipta$1,125$15,96515 claims
Upsher-smith Laboratories LLCTopiramate$57$2,143155 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$354$1,42511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 388 neurology providers in Arizona.

Other neurology in Glendale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →